Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies
Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treat...
Gespeichert in:
Veröffentlicht in: | International journal of molecular sciences 2024-10, Vol.25 (20), p.11055 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 20 |
container_start_page | 11055 |
container_title | International journal of molecular sciences |
container_volume | 25 |
creator | Nammour, Helena M Madrigal, Karla Starling, Caroline T Doan, Hung Q |
description | Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treatment are met with sparse alternatives and a grim prognosis. For this reason, it is of interest to expand the repertoire of available therapies for MCC patients who remain resistant to current primary interventions. Recently, our improved mechanistic understanding of aberrant cell signaling observed in both MCPyV-positive and -negative MCC has facilitated exploration into several small molecules and inhibitors, among them receptor tyrosine kinase inhibitors (TKIs) and somatostatin analogs (SSAs), both of which have positively improved response rates and reduced tumor volumes upon application to treatment of MCC. The introduction of such targeted therapies into treatment protocols holds promise for more personalized care tailored towards patients of diverse subtypes, thereby improving outcomes and mitigating tumor burden, especially for treatment-resistant individuals. In this review, we characterize recent findings surrounding targeted treatments that have been applied to MCC and provide an overview of emerging perspectives on translatable options that can be further developed to offer additional therapeutic avenues for patients with the disease. |
doi_str_mv | 10.3390/ijms252011055 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11507330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A814393051</galeid><sourcerecordid>A814393051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-3141b393afc294d2a276928bea72b1f83ba4403dda6dda42b2e21fb9a049f4923</originalsourceid><addsrcrecordid>eNptkstv1DAQxi0Eog84ckWWuHBJGb-yay5otaIPqagSCicOlpOMt16SeLGTRfz3ddRSughZY4_s33zWZw8hbxicCaHhg9_2iSsOjIFSz8gxk5wXAOXi-ZP8iJyktAXggiv9khwJLVW5VOKYfF-1ezs0ftjQKqIdexxGerMbfRgSdSHSLxh_YEfX2OXJxkyG3n6kK_oV9x5_0eBoNfUhFpWNGxyxpdUtRrvzmF6RF852CV8_rKfk2_nnan1ZXN9cXK1X10UjSj0WgklWCy2sa7iWLbd8UWq-rNEueM3cUtRWShBta8scktccOXO1tiC1k5qLU_LpXnc31T22TbYQbWd20fc2_jbBenN4Mvhbswl7w5iChRCQFd4_KMTwc8I0mt6nJlu2A4YpGcE4gxK0mtF3_6DbMMUh-5spKGUJnP2lNrZD4wcX8sXNLGpWSyazW1AzdfYfKo8We9-EAZ3P-wcFxX1BE0NKEd2jSQZmbgdz0A6Zf_v0ZR7pP_8v7gDthq7n</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120646021</pqid></control><display><type>article</type><title>Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Nammour, Helena M ; Madrigal, Karla ; Starling, Caroline T ; Doan, Hung Q</creator><creatorcontrib>Nammour, Helena M ; Madrigal, Karla ; Starling, Caroline T ; Doan, Hung Q</creatorcontrib><description>Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treatment are met with sparse alternatives and a grim prognosis. For this reason, it is of interest to expand the repertoire of available therapies for MCC patients who remain resistant to current primary interventions. Recently, our improved mechanistic understanding of aberrant cell signaling observed in both MCPyV-positive and -negative MCC has facilitated exploration into several small molecules and inhibitors, among them receptor tyrosine kinase inhibitors (TKIs) and somatostatin analogs (SSAs), both of which have positively improved response rates and reduced tumor volumes upon application to treatment of MCC. The introduction of such targeted therapies into treatment protocols holds promise for more personalized care tailored towards patients of diverse subtypes, thereby improving outcomes and mitigating tumor burden, especially for treatment-resistant individuals. In this review, we characterize recent findings surrounding targeted treatments that have been applied to MCC and provide an overview of emerging perspectives on translatable options that can be further developed to offer additional therapeutic avenues for patients with the disease.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms252011055</identifier><identifier>PMID: 39456853</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antimitotic agents ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Cancer ; Cancer therapies ; Carcinoma ; Carcinoma, Merkel Cell - drug therapy ; Carcinoma, Merkel Cell - pathology ; Carcinoma, Merkel Cell - therapy ; Care and treatment ; Cell growth ; Clinical trials ; Development and progression ; Health aspects ; Humans ; Immunotherapy ; Kinases ; Lanreotide ; Ligands ; Metastasis ; Molecular Targeted Therapy - methods ; Mutation ; Pathogenesis ; Protein Kinase Inhibitors - therapeutic use ; Response rates ; Review ; Skin ; Skin cancer ; Skin Neoplasms - drug therapy ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; Tumorigenesis ; Tumors ; Tyrosine ; Vascular endothelial growth factor</subject><ispartof>International journal of molecular sciences, 2024-10, Vol.25 (20), p.11055</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c369t-3141b393afc294d2a276928bea72b1f83ba4403dda6dda42b2e21fb9a049f4923</cites><orcidid>0000-0003-4540-9363 ; 0000-0002-4715-0562 ; 0009-0000-5531-7636 ; 0009-0009-1872-9741</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11507330/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11507330/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39456853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nammour, Helena M</creatorcontrib><creatorcontrib>Madrigal, Karla</creatorcontrib><creatorcontrib>Starling, Caroline T</creatorcontrib><creatorcontrib>Doan, Hung Q</creatorcontrib><title>Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treatment are met with sparse alternatives and a grim prognosis. For this reason, it is of interest to expand the repertoire of available therapies for MCC patients who remain resistant to current primary interventions. Recently, our improved mechanistic understanding of aberrant cell signaling observed in both MCPyV-positive and -negative MCC has facilitated exploration into several small molecules and inhibitors, among them receptor tyrosine kinase inhibitors (TKIs) and somatostatin analogs (SSAs), both of which have positively improved response rates and reduced tumor volumes upon application to treatment of MCC. The introduction of such targeted therapies into treatment protocols holds promise for more personalized care tailored towards patients of diverse subtypes, thereby improving outcomes and mitigating tumor burden, especially for treatment-resistant individuals. In this review, we characterize recent findings surrounding targeted treatments that have been applied to MCC and provide an overview of emerging perspectives on translatable options that can be further developed to offer additional therapeutic avenues for patients with the disease.</description><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma</subject><subject>Carcinoma, Merkel Cell - drug therapy</subject><subject>Carcinoma, Merkel Cell - pathology</subject><subject>Carcinoma, Merkel Cell - therapy</subject><subject>Care and treatment</subject><subject>Cell growth</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Lanreotide</subject><subject>Ligands</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Mutation</subject><subject>Pathogenesis</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Response rates</subject><subject>Review</subject><subject>Skin</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><subject>Tyrosine</subject><subject>Vascular endothelial growth factor</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkstv1DAQxi0Eog84ckWWuHBJGb-yay5otaIPqagSCicOlpOMt16SeLGTRfz3ddRSughZY4_s33zWZw8hbxicCaHhg9_2iSsOjIFSz8gxk5wXAOXi-ZP8iJyktAXggiv9khwJLVW5VOKYfF-1ezs0ftjQKqIdexxGerMbfRgSdSHSLxh_YEfX2OXJxkyG3n6kK_oV9x5_0eBoNfUhFpWNGxyxpdUtRrvzmF6RF852CV8_rKfk2_nnan1ZXN9cXK1X10UjSj0WgklWCy2sa7iWLbd8UWq-rNEueM3cUtRWShBta8scktccOXO1tiC1k5qLU_LpXnc31T22TbYQbWd20fc2_jbBenN4Mvhbswl7w5iChRCQFd4_KMTwc8I0mt6nJlu2A4YpGcE4gxK0mtF3_6DbMMUh-5spKGUJnP2lNrZD4wcX8sXNLGpWSyazW1AzdfYfKo8We9-EAZ3P-wcFxX1BE0NKEd2jSQZmbgdz0A6Zf_v0ZR7pP_8v7gDthq7n</recordid><startdate>20241015</startdate><enddate>20241015</enddate><creator>Nammour, Helena M</creator><creator>Madrigal, Karla</creator><creator>Starling, Caroline T</creator><creator>Doan, Hung Q</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4540-9363</orcidid><orcidid>https://orcid.org/0000-0002-4715-0562</orcidid><orcidid>https://orcid.org/0009-0000-5531-7636</orcidid><orcidid>https://orcid.org/0009-0009-1872-9741</orcidid></search><sort><creationdate>20241015</creationdate><title>Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies</title><author>Nammour, Helena M ; Madrigal, Karla ; Starling, Caroline T ; Doan, Hung Q</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-3141b393afc294d2a276928bea72b1f83ba4403dda6dda42b2e21fb9a049f4923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma</topic><topic>Carcinoma, Merkel Cell - drug therapy</topic><topic>Carcinoma, Merkel Cell - pathology</topic><topic>Carcinoma, Merkel Cell - therapy</topic><topic>Care and treatment</topic><topic>Cell growth</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Lanreotide</topic><topic>Ligands</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Mutation</topic><topic>Pathogenesis</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Response rates</topic><topic>Review</topic><topic>Skin</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><topic>Tyrosine</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nammour, Helena M</creatorcontrib><creatorcontrib>Madrigal, Karla</creatorcontrib><creatorcontrib>Starling, Caroline T</creatorcontrib><creatorcontrib>Doan, Hung Q</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nammour, Helena M</au><au>Madrigal, Karla</au><au>Starling, Caroline T</au><au>Doan, Hung Q</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-10-15</date><risdate>2024</risdate><volume>25</volume><issue>20</issue><spage>11055</spage><pages>11055-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treatment are met with sparse alternatives and a grim prognosis. For this reason, it is of interest to expand the repertoire of available therapies for MCC patients who remain resistant to current primary interventions. Recently, our improved mechanistic understanding of aberrant cell signaling observed in both MCPyV-positive and -negative MCC has facilitated exploration into several small molecules and inhibitors, among them receptor tyrosine kinase inhibitors (TKIs) and somatostatin analogs (SSAs), both of which have positively improved response rates and reduced tumor volumes upon application to treatment of MCC. The introduction of such targeted therapies into treatment protocols holds promise for more personalized care tailored towards patients of diverse subtypes, thereby improving outcomes and mitigating tumor burden, especially for treatment-resistant individuals. In this review, we characterize recent findings surrounding targeted treatments that have been applied to MCC and provide an overview of emerging perspectives on translatable options that can be further developed to offer additional therapeutic avenues for patients with the disease.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39456853</pmid><doi>10.3390/ijms252011055</doi><orcidid>https://orcid.org/0000-0003-4540-9363</orcidid><orcidid>https://orcid.org/0000-0002-4715-0562</orcidid><orcidid>https://orcid.org/0009-0000-5531-7636</orcidid><orcidid>https://orcid.org/0009-0009-1872-9741</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1422-0067 |
ispartof | International journal of molecular sciences, 2024-10, Vol.25 (20), p.11055 |
issn | 1422-0067 1661-6596 1422-0067 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11507330 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
subjects | Antimitotic agents Antineoplastic agents Antineoplastic Agents - therapeutic use Cancer Cancer therapies Carcinoma Carcinoma, Merkel Cell - drug therapy Carcinoma, Merkel Cell - pathology Carcinoma, Merkel Cell - therapy Care and treatment Cell growth Clinical trials Development and progression Health aspects Humans Immunotherapy Kinases Lanreotide Ligands Metastasis Molecular Targeted Therapy - methods Mutation Pathogenesis Protein Kinase Inhibitors - therapeutic use Response rates Review Skin Skin cancer Skin Neoplasms - drug therapy Skin Neoplasms - pathology Skin Neoplasms - therapy Tumorigenesis Tumors Tyrosine Vascular endothelial growth factor |
title | Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A38%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advancing%20Treatment%20Options%20for%20Merkel%20Cell%20Carcinoma:%20A%20Review%20of%20Tumor-Targeted%20Therapies&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Nammour,%20Helena%20M&rft.date=2024-10-15&rft.volume=25&rft.issue=20&rft.spage=11055&rft.pages=11055-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms252011055&rft_dat=%3Cgale_pubme%3EA814393051%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3120646021&rft_id=info:pmid/39456853&rft_galeid=A814393051&rfr_iscdi=true |